Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.870
+0.030 (1.63%)
At close: Dec 20, 2024, 4:00 PM
1.900
+0.030 (1.60%)
After-hours: Dec 20, 2024, 5:42 PM EST
Allogene Therapeutics Employees
As of December 31, 2023, Allogene Therapeutics had 233 total employees, including 232 full-time and 1 part-time employees. The number of employees decreased by 128 or -35.46% compared to the previous year.
Employees
233
Change (1Y)
-128
Growth (1Y)
-35.46%
Revenue / Employee
$185
Profits / Employee
-$1,216,433
Market Cap
392.09M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Enhabit | 10,800 |
Quanterix | 441 |
Alpha Teknova | 211 |
Akebia Therapeutics | 167 |
Nano-X Imaging | 164 |
KalVista Pharmaceuticals | 150 |
Monte Rosa Therapeutics | 133 |
Y-mAbs Therapeutics | 100 |
ALLO News
- 5 days ago - Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 9 days ago - Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics Announces Participation in December Investor Conferences - GlobeNewsWire
- 4 weeks ago - Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence - GlobeNewsWire
- 6 weeks ago - Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 6 weeks ago - Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS - GlobeNewsWire
- 6 weeks ago - Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire